kabutan

KYORIN Pharma, First Half Ordinary Profit Decreases by 23%, Jul-Sep Ordinary Profit Turns to Loss

Fri Nov 7, 2025 3:30 pm JST Earnings

4569 KYORIN Pharmaceutical Co.,Ltd. 【J-GAAP】

Earnings Report

KYORIN Pharmaceutical Co.,Ltd. <4569> [TSE Prime] announced its financial results after the market closed on November 7th (15:30). The consolidated ordinary profit for the cumulative second quarter of the fiscal year ending March 2026 (April to September) decreased 22.8% from the same period last year to 1.58 billion yen. Progress toward the full-year plan of 6.30 billion yen was 25.1%, which was higher than the five-year average of 18.4%.

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the October to March period (second half) is expected to significant drop 57.8% from the same period last year to 4.71 billion yen.

In the most recent three-month period, from July to September (2Q), the consolidated ordinary profit/loss turned to a loss of 1.04 billion yen (compared to a profit of 0.63 billion yen in the same period last year). The operating profit/loss margin drastically worsened from 1.5% in the same period last year to -3.5%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Sep, 2023 54,937 1,335 1,578 1,890 33.0 23.1 Nov 8, 2023 J-GAAP
Apr - Sep, 2024 55,139 1,549 2,050 1,255 21.9 15.5 Nov 7, 2024 J-GAAP
Apr - Sep, 2025 58,731 1,363 1,582 1,494 26.0 25.1 Nov 7, 2025 J-GAAP
YoY +6.5% -12.0% -22.8% +19.0% +19.0%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2025 Guidance 57,400 1,700 1,800 1,400 24.4 20 May 12, 2025 J-GAAP
Apr - Sep, 2025 Results 58,731 1,363 1,582 1,494 26.0 20 Nov 7, 2025 J-GAAP
Revision Rate +2.3% -19.8% -12.1% +6.7% +6.7%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 74,948 11,018 11,169 7,831 136.3 37 May 12, 2025 J-GAAP
Oct - Mar, 2025 Guidance 68,269 4,737 4,718 3,306 57.6 37 Nov 7, 2025 J-GAAP
YoY -8.9% -57.0% -57.8% -57.8% -57.8%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 119,532 6,234 6,822 5,475 95.4 52 May 10, 2024 J-GAAP
Mar, 2025 130,087 12,567 13,219 9,086 158.2 57 May 12, 2025 J-GAAP
Mar, 2026 Guidance 127,000 6,100 6,300 4,800 83.6 57 May 12, 2025 J-GAAP
YoY -2.4% -51.5% -52.3% -47.2% -47.2%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2024 26,720 399 633 370 6.4 1.5 Nov 7, 2024 J-GAAP
Oct - Dec, 2024 34,147 1,566 1,703 1,184 20.6 4.6 Feb 5, 2025 J-GAAP
Jan - Mar, 2025 40,801 9,452 9,466 6,647 115.7 23.2 May 12, 2025 J-GAAP
Apr - Jun, 2025 30,229 2,368 2,624 2,100 36.6 7.8 Jul 31, 2025 J-GAAP
Jul - Sep, 2025 28,502 -1,005 -1,042 -606 -10.6 -3.5 Nov 7, 2025 J-GAAP
YoY +6.7% － － － －

Related Articles